Literature DB >> 18508211

Solid lipid nanoparticles for retinal gene therapy: transfection and intracellular trafficking in RPE cells.

A del Pozo-Rodríguez1, D Delgado, M A Solinís, A R Gascón, J L Pedraz.   

Abstract

Retinal pigment epithelial (RPE) cells are usually employed to study DNA systems for diseases related to problems in the retina. Solid lipid nanoparticles (SLNs) have been shown to be useful non-viral vectors for gene therapy. The objective of this work was to evaluate the transfection capacity of SLNs in the human retinal pigment epithelial established cell line (ARPE-19) in order to elucidate the potential application of this vector in the treatment of retinal diseases. Results showed a lower transfection level of SLNs in ARPE-19 cells than in HEK293 (2.5% vs. 14.9% EGFP positive cells at 72h post-transfection). Trafficking studies revealed a delay in cell uptake of the vectors in ARPE-19 cells. Differences in internalization process into the two cell lines studied explain, in part, the difference in the gene expression. The clathrin-mediated endocytosis in ARPE-19 cells directs the solid lipid nanoparticles to lysosomes; moreover, the low division rate of this cell line hampers the entrance of DNA into the nucleus. The knowledge of intracellular trafficking is very useful in order to design more efficient vectors taking into account the characteristics of the specific cell line to be transfected.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18508211     DOI: 10.1016/j.ijpharm.2008.04.023

Source DB:  PubMed          Journal:  Int J Pharm        ISSN: 0378-5173            Impact factor:   5.875


  16 in total

Review 1.  Nanoparticles for retinal gene therapy.

Authors:  Shannon M Conley; Muna I Naash
Journal:  Prog Retin Eye Res       Date:  2010-05-07       Impact factor: 21.198

2.  Nanoparticles in the ocular drug delivery.

Authors:  Hong-Yan Zhou; Ji-Long Hao; Shuang Wang; Yu Zheng; Wen-Song Zhang
Journal:  Int J Ophthalmol       Date:  2013-06-18       Impact factor: 1.779

3.  A novel formulation based on 2,3-di(tetradecyloxy)propan-1-amine cationic lipid combined with polysorbate 80 for efficient gene delivery to the retina.

Authors:  Gustavo Puras Ochoa; Jon Zárate Sesma; Mireia Agirre Díez; Ariadna Díaz-Tahoces; Marcelino Avilés-Trigeros; Santiago Grijalvo; Ramón Eritja; Eduardo Fernández; Jose Luis Pedraz
Journal:  Pharm Res       Date:  2014-01-22       Impact factor: 4.200

Review 4.  Nanoparticle-based technologies for retinal gene therapy.

Authors:  Jeffrey Adijanto; Muna I Naash
Journal:  Eur J Pharm Biopharm       Date:  2015-01-12       Impact factor: 5.571

5.  Development and characterization of nanoparticulate formulation of a water soluble prodrug of dexamethasone by HIP complexation.

Authors:  Ripal Gaudana; Ashwin Parenky; Ravi Vaishya; Swapan K Samanta; Ashim K Mitra
Journal:  J Microencapsul       Date:  2010-10-12       Impact factor: 3.142

6.  Hydroxyl PAMAM dendrimer-based gene vectors for transgene delivery to human retinal pigment epithelial cells.

Authors:  Panagiotis Mastorakos; Siva P Kambhampati; Manoj K Mishra; Tony Wu; Eric Song; Justin Hanes; Rangaramanujam M Kannan
Journal:  Nanoscale       Date:  2015-03-07       Impact factor: 7.790

7.  Nano-vectors for the Ocular Delivery of Nucleic Acid-based Therapeutics.

Authors:  R K Khar; G K Jain; M H Warsi; N Mallick; S Akhter; S A Pathan; F J Ahmad
Journal:  Indian J Pharm Sci       Date:  2010-11       Impact factor: 0.975

8.  Poly(β-amino ester)-nanoparticle mediated transfection of retinal pigment epithelial cells in vitro and in vivo.

Authors:  Joel C Sunshine; Sarah B Sunshine; Imran Bhutto; James T Handa; Jordan J Green
Journal:  PLoS One       Date:  2012-05-21       Impact factor: 3.240

Review 9.  Lipid Nanoparticles for Ocular Gene Delivery.

Authors:  Yuhong Wang; Ammaji Rajala; Raju V S Rajala
Journal:  J Funct Biomater       Date:  2015-06-08

10.  Multicomponent nanoparticles as nonviral vectors for the treatment of Fabry disease by gene therapy.

Authors:  Aritz Pérez Ruiz de Garibay; Diego Delgado; Ana Del Pozo-Rodríguez; María Ángeles Solinís; Alicia Rodríguez Gascón
Journal:  Drug Des Devel Ther       Date:  2012-10-26       Impact factor: 4.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.